VamsidharVelchetiMDFACP FCCP

Oncology • New York, NY

Hematologic Oncology, Thoracic Cancer

Director, Thoracic Oncology Program, New York University

Join to view full profile

Dr. Velcheti is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Velcheti's full profile

Already have an account?

Office
160 East 34th Street
8th Floor
New York, NY 10016
Phone+1 212-731-5662
Is this information wrong?

Summary

Vamsidhar Velcheti, MD FACP FCCP is a medical oncologist with expertise in thoracic oncology and cancer immunotherapy. He is currently a Staff physician and Associate Director of Center for Immuno-Oncology Research at the Cleveland Clinic in Cleveland, OH. His current work focuses on novel immunotherapy strategies to treat lung cancer and biomarker discovery. He is interested in clinical trial design and incorporation of biomarker studies into early drug trials.

Education & Training

Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2010 - 2013
Ochsner Clinic FoundationResidency, Internal Medicine, 2007 - 2010
ArMed Forces Medical College PuneClass of 2003

Certifications & Licensure

NY State Medical License 2018 - 2026
OH State Medical License 2013 - 2019
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Career development Award American Society of Clinical Oncology, 2015
Scott Hamilton CARES initiative research award 2015
ASCO Merit Award American Society of Clinical Oncology, 2013
Outstanding researcher of the year Yale Cancer Center/Hematology Oncology Fellowship program, 2013
Young Investigator American Society of Clinical Oncology, 2012
The Edward D. Frohlich Award Ochsner Clinic Foundation, 2010
Resident Researcher of the year Internal Medicine Program, Ochsner Clinic Foundation, 2010
Travel Scholarship American Society of Hematology in San Francisco, CA, 2008
Certificate of Merit and Excellence in design Radiological Society of North America, 2005
College Blues Award, Student Scientific Society Armed Forces Medical College, 2002
Join now to see all

Clinical Trials

Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors Start of enrollment: 2010 Oct 01
Completed
Phase 1
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer Start of enrollment: 2013 Feb 01
Terminated
Phase 2, Phase 3
Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung Start of enrollment: 2013 Apr 05
Completed
Phase 2
A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors Start of enrollment: 2014 May 01
Completed
Phase 1
A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer Start of enrollment: 2014 Jan 22
Completed
Phase 2
A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021) Start of enrollment: 2014 Feb 21
Completed
Phase 1, Phase 2
Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer Start of enrollment: 2014 Jun 16
Terminated
Phase 2
TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy Start of enrollment: 2014 Nov 01
Terminated
Phase 2, Phase 3
MK-3475 as Maintenance Therapy in Extensive Stage SCLC Start of enrollment: 2015 Feb 01
Completed
Phase 2
A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer Start of enrollment: 2015 Apr 15
Completed
Phase 1, Phase 2
Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) Start of enrollment: 2015 Jul 21
Active, not recruiting
Phase 3
ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer Start of enrollment: 2016 Jan 08
Completed
Phase 1, Phase 2
Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab Start of enrollment: 2016 Jan 01
Completed
Phase 1
Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors Start of enrollment: 2017 May 31
Active, not recruiting
Phase 1
Pembrolizumab Alone or Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC Start of enrollment: 2017 Jun 07
Completed
Phase 2
A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients Start of enrollment: 2017 Jan 01
Withdrawn
Phase 1, Phase 2
Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With NSCLC: PRECISE Trial Start of enrollment: 2017 Jun 06
Active, not recruiting
Phase 2
Nivolumab Alone or in Combination With Decitabine/Tetrahydrouridine in Non-small Cell Lung Cancer Start of enrollment: 2016 Sep 01
A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors Start of enrollment: 2016 Jul 01
Completed
Phase 1, Phase 2
A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer Start of enrollment: 2016 Oct 01
Terminated
Phase 1
A Study of Atezolizumab as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer Start of enrollment: 2016 Sep 23
Completed
Phase 2
Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer Start of enrollment: 2017 Aug 14
Active, not recruiting
Phase 2
Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in NSCLC Start of enrollment: 2017 May 19
Terminated
Phase 1
An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2017 Mar 29
Completed
Phase 2
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements Start of enrollment: 2017 Mar 07
Recruiting
Phase 1, Phase 2
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) Start of enrollment: 2017 May 02
Recruiting
Phase 1, Phase 2
Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer Start of enrollment: 2019 Apr 05
Active, not recruiting
Phase 3
Study to Investigate DRP-104 in Adults With Advanced Solid Tumors Start of enrollment: 2020 Aug 31
Terminated
Phase 1, Phase 2
VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer Start of enrollment: 2022 Nov 09
Terminated
Phase 1
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) Start of enrollment: 2021 Feb 17
Active, not recruiting
Phase 2
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities Start of enrollment: 2020 Dec 16
Recruiting
Phase 1, Phase 2
Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-Small Cell Lung Cancer Who Have Progressed on Prior Anti- Programmed Death-ligand 1 (PD-[L]1) Therapy and Chemotherapy Start of enrollment: 2020 Dec 08
Active, not recruiting
Phase 2, Phase 3
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-small Cell Lung Cancer Start of enrollment: 2020 Oct 26
Active, not recruiting
Phase 3
Immunotherapy With Non-Ablative Radiation in Previously Untreated Patients With Stage IV NSCLC Start of enrollment: 2023 Jan 24
Recruiting
Phase 2
Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC Start of enrollment: 2020 Oct 08
Recruiting
Phase 2
Apricity CARE to Improve ICI Outcomes of Ethnic/Racial Minority NSCLC Patients Start of enrollment: 2023 Apr 01
Not yet recruiting
Not Applicable
Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer Start of enrollment: 2022 Oct 05
Recruiting
Phase 1
A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors Start of enrollment: 2023 Nov 09
Active, not recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

2 citations
Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer.
Xinyuan Tong, Ayushi S Patel, Eejung Kim, Hongjun Li, Yueqing Chen, Shuai Li, Shengwu Liu, Julien Dilly, Kevin S Kapner, Ningxia Zhang, Yun Xue, Laura Hover, Suman Muk...> ;Cancer Cell. 2024 Mar 11
To Crush or Not to Crush: Administering Dabrafenib and Trametinib Through a Nasogastric Tube in a Critically Ill Patient With Nonsmall Cell Lung Cancer - A Case Report...
Jang, C., Lau, S., Velcheti, V.> ;Clinical Lung Cancer. 2023 Dec 27
Objective Analysis and Clinical Significance of the Spatial Tumor-Infiltrating Lymphocyte Patterns in Non-Small Cell Lung Cancer.
Wang, Y., Peng, G., Gu, J., Gainor, J., Mino-Kenudson, M., Riess, J., Velcheti, V., Hellmann, M., Zhao, H., Schalper, K., Lopez de Rodas, M.> ;Clinical Cancer Research. 2024 Mar 1
1 citations
Pathomic Features Reveal Immune and Molecular Evolution From Lung Preneoplasia to Invasive Adenocarcinoma.
Chen, P., Rojas, F., Hu, X., Serrano, A., Zhu, B., Chen, H., Hong, L., Bandyoyadhyay, R., Aminu, M., Kalhor, N., Lee, J., El Hussein, S., Khoury, J., Pass, H., Moreira...> ;Modern Pathology. 2023 Dec 1
Long-term benefit of sotorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: plain language summary.
Grace K Dy, Ramaswamy Govindan, Vamsidhar Velcheti, Gerald S Falchook, Antoine Italiano, Jürgen Wolf, Adrian G Sacher, Toshiaki Takahashi, Suresh S Ramalingam, Christo...> ;Future Oncology. 2024 Jan 1
Inflammation in the tumor-adjacent lung as a predictor of clinical outcome in lung adenocarcinoma.
Igor Dolgalev, Hua Zhou, Nina Murrell, Hortense Le, Theodore Sakellaropoulos, Nicolas Coudray, Kelsey Zhu, Varshini Vasudevaraja, Anna Yeaton, Chandra Goparaju, Yonghu...> ;Nature Communications. 2023 Nov 8
2 citations
Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy.
Suman Mukhopadhyay, Hsin-Yi Huang, Ziyan Lin, Michela Ranieri, Shuai Li, Soumyadip Sahu, Yingzhuo Liu, Yi Ban, Kayla Guidry, Hai Hu, Alfonso Lopez, Fiona Sherman, Yi J...> ;Cancer Research. 2023 Dec 15
Trends in Lung Cancer Incidence and Mortality (1990-2019) in the United States: A Comprehensive Analysis of Gender and State-Level Disparities.
Singh, H., Abdallah, N., Mouchati, C., Arora, S., Salciccioli, J., Thomson, C., Jani, C., Kareff, S., Velcheti, V.> ;JCO Global Oncology. 2023 Sep 1
Neuroendocrine lineage commitment of small cell lung cancers can be leveraged into p53-independent non-cytotoxic therapy.
Sudipta Biswas, Kai Kang, Kwok Peng Ng, Tomas Radivoyevitch, Kurt Schalper, Hua Zhang, Daniel J Lindner, Anish Thomas, David MacPherson, Brian Gastman, David S Schrump...> ;Cell Reports. 2023 Aug 29
5 citations
Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions.
Zofia Piotrowska, Daniel Shao-Weng Tan, Egbert F Smit, Alexander I Spira, Danny Nguyen, Victor Ho-Fun Lee, James Chih-Hsin Yang, Vamsidhar Velcheti, John M Wrangle, Ma...> ;Journal of Clinical Oncology. 2023 Sep 10
6 citations
Deep computational image analysis of immune cell niches reveals treatment-specific outcome associations in lung cancer.
Cristian Barrera, Germán Corredor, Vidya Sankar Viswanathan, Ruiwen Ding, Paula Toro, Pingfu Fu, Christina Buzzy, Cheng Lu, Priya Velu, Philipp Zens, Sabina Berezowska...> ;NPJ Precision Oncology. 2023 Jun 1
12 citations
Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study.
Maliazurina B Saad, Lingzhi Hong, Muhammad Aminu, Natalie I Vokes, Pingjun Chen, Morteza Salehjahromi, Kang Qin, Sheeba J Sujit, Xuetao Lu, Elliana Young, Qasem Al-Tas...> ;The Lancet. Digital Health. 2023 Jul 1
12 citations
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer.
Arvind Ravi, Matthew D Hellmann, Monica B Arniella, Mark Holton, Samuel S Freeman, Vivek Naranbhai, Chip Stewart, Ignaty Leshchiner, Jaegil Kim, Yo Akiyama, Aaron T Gr...> ;Nature Genetics. 2023 May 1
14 citations
Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With PretreatedG12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100.
Grace K Dy, Ramaswamy Govindan, Vamsidhar Velcheti, Gerald S Falchook, Antoine Italiano, Jürgen Wolf, Adrian G Sacher, Toshiaki Takahashi, Suresh S Ramalingam, Christo...> ;Journal of Clinical Oncology. 2023 Jun 20
A Phase I Study of a Combination of Liposomal Irinotecan and Veliparib in Solid Tumors.
Meredith LaRose, Roisin M Connolly, Ciara C O'Sullivan, Vamsidhar Velcheti, Rasa Vilimas, Katherine Gano, Susan E Bates, Yves Pommier, Anish Thomas> ;The Oncologist. 2023 May 8
A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer.
Wade T Iams, Meridith L Balbach, Sharon Phillips, Adrian Sacher, Christine Bestvina, Vamsidhar Velcheti, Xiao Wang, Melina E Marmarelis, Nan Sethakorn, Ticiana Leal, P...> ;Clinical Lung Cancer. 2023 May 1
2 citations
Extended Survival in Patients With Non-Small-Cell Lung Cancer-Associated Brain Metastases in the Modern Era.
Assaf Berger, Reed Mullen, Kenneth Bernstein, Juan Diego Alzate, Joshua S Silverman, Erik P Sulman, Bernadine R Donahue, Abraham Chachoua, Elaine Shum, Vamsidhar Velch...> ;Neurosurgery. 2023 Jul 1
11 citations
KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition.
Yuanwang Pan, Han Han, Hai Hu, Hua Wang, Yueqiang Song, Yuan Hao, Xinyuan Tong, Ayushi S Patel, Selim Misirlioglu, Sittinon Tang, Hsin-Yi Huang, Ke Geng, Ting Chen, An...> ;Cancer Cell. 2023 Jan 9
6 citations
A tumor vasculature-based imaging biomarker for predicting response and survival in patients with lung cancer treated with checkpoint inhibitors.
Mehdi Alilou, Mohammadhadi Khorrami, Prateek Prasanna, Kaustav Bera, Amit Gupta, Vidya Sankar Viswanathan, Pradnya Patil, Priya Darsini Velu, Pingfu Fu, Vamsidhar Velc...> ;Science Advances. 2022 Nov 25
16 citations
Squamous cell lung cancer: Current landscape and future therapeutic options.
Sally C M Lau, Yuanwang Pan, Vamsidhar Velcheti, Kwok Kin Wong> ;Cancer Cell. 2022 Nov 14
3 citations
Nemvaleukin alfa, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer.
Yuanwang Pan, Yuan Hao, Han Han, Ting Chen, Hailin Ding, Kristen E Labbe, Elaine Shum, Kayla Guidry, Hai Hu, Fiona Sherman, Ke Geng, Janaye Stephens, Alison Chafitz, S...> ;Journal for Immunotherapy of Cancer. 2022 Sep 1
94 citations
The current state of the art and future trends in RAS-targeted cancer therapies.
Salman R Punekar, Vamsidhar Velcheti, Benjamin G Neel, Kwok-Kin Wong> ;Nature Reviews. Clinical Oncology. 2022 Oct 1
36 citations
Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung Cancer.
Joshua K Sabari, Vamsidhar Velcheti, Kazuhide Shimizu, Matthew R Strickland, Rebecca S Heist, Mohini Singh, Naema Nayyar, Anita Giobbie-Hurder, Subba R Digumarthy, Jus...> ;Clinical Cancer Research. 2022 Aug 2
31 citations
Immunotherapy in non-small cell lung cancer: Past, present, and future directions.
Salman R Punekar, Elaine Shum, Cassandra Mia Grello, Sally C Lau, Vamsidhar Velcheti> ;Frontiers in Oncology. 2022 Jan 1
6 citations
A Phase 1 Study of Concurrent Neoadjuvant Pembrolizumab Plus Chemoradiation Followed by Consolidation Pembrolizumab in Patients With Resectable Stage IIIA NSCLC.
Christopher A Lemmon, Gregory M M Videtic, Sudish Murthy, Kevin L Stephans, Marc Shapiro, Usman Ahmad, Daniel Raymond, Vamsidhar Velcheti, Alejandro Bribriesco, Xuefei...> ;JTO Clinical and Research Reports. 2022 Jul 1
Join now to see all

Books/Book Chapters

Oncologic Emergencies in The Washington Manual of Oncology.
Velcheti V and Govindan, RLippincott Williams & Wilkins, Philadelphia, PennsylvaniaEdition 2,
Lung Cancer in The Washington Sub-speciality Manual of hematology& Oncology.
Velcheti V and Subramanian, JLippincott Williams & Wilkins, Philadelphia, PennsylvaniaEdition 2,
Lung Cancer in Internal Medicine Just the facts.
Velcheti V and Govindan, RLippincott Williams & Wilkins, Philadelphia, PennsylvaniaEdition 2,
Complementary, Alternative, and Integrative Therapies in Cancer Care in Principles and Practice of Oncology.
Velcheti VEditors: Govindan, R.Lippincott Wilkins and Williams
Join now to see all

Abstracts/Posters

Molecular Subtyping to Predict Risk of Venous Thromboembolism in Patients with Advanced Lung Adenocarcinoma: A Cohort Study
Vamsidhar Velcheti, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Retrospective EHR Study on Effectiveness of Eltrombopag in Cancer Treatment-Related Thrombocytopenia
Vamsidhar Velcheti, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Non-small cell lung cancer (NSCLC) in octogenarians.
Velcheti V., Viswanathan, A., Sainani, N., Grove, L., Suresh, R., Baggstrom, M.Q., and Govindan, R, Proc Am SocClinOnc, 2006; abst # 1855
Clinical utility of routinely adding positron emission tomography (PET) to computer tomography (CT) and endoscopic ultrasound (EUS) in the initial staging of esophagea...
Velcheti V, Viswanathan A, Badhey N, Gao F, Peifer K, Edmundowicz S, Early D, Govindan R, Azar R, American College of Chest Physicians 2006 annual meeting in Salt Lake City
Distinctive characteristics of non-small cell lung cancer in younger paitents: A national cancer database (NCDB) analysis of patients under 40 years old (1998-2003).
Velcheti V., Goodgame B., Morgensztern D., Gao F., Baggstrom M., Govindan R, Proc Am SocClinOnc, 2007;abst #18035
Barriers for accrual to clinical trials in adult patients (pts) with non-small cell lung cancer.
Baggstrom M, Velcheti V, Malik M, Gilstrap E, Skelton A, Lange K, Foersterling D, Govindan R, 12th World Conference on Lung Cancer, Seoul, Korea
Distinctive characteristics of non-small cell lung cancer (NSCLC) in the young: Washington University experience.
Subramanian J, Velcheti V, Goodgame B, Morgensztern D, Gao F, Baggstrom M, Govindan R, 12th World Conference on Lung Cancer, Seoul, Korea
Distinctive characteristics of extrapulmonary small cell carcinoma: A Surveillance Epidemiology and End Results (SEER) snalysis.
Subramanian J., Velcheti V, Goodgame B.W., Govindan R., Morgensztern D, Proc Am SocClinOnc, 2008; abst #22106
Preclinical evaluation of bafetinib for treatment of glioblastomamultiforme.
Velcheti V, Peterson B, Levitt D J, Li L, Rodwig F, Prakash O, J Clin Oncol (Meeting Abstracts) May 2010 vol. 28 no.15_suppl 2082
Join now to see all

Lectures

Prospective clinical evaluation of blood-based tumor mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCL...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/5/2018
Cytokines in Cancer Immunotherapy: Recent Updates
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Overcoming Resistance to Immune Checkpoint Blockade
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Authored Content

WCLC 2021: Cracking the 'Undruggable' KRAS Problem in Lung CancerSeptember 2021
Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
Join now to see all

Press Mentions

New AI-Based Biomarker May Help Predict Immunotherapy Response for Patients with NSCLCJanuary 11th, 2023
NYU Langone Doctor Stresses Anyone Can Get Lung Cancer, Even if Not a SmokerNovember 3rd, 2022
Cancer Treatment Predictor May Not Work in Patients with African and Asian AncestriesOctober 4th, 2022
Join now to see all

Grant Support

Cleveland Clinic Research Program Committee Research AwardCleveland Clinic Lerner Research Institute2014–Present
Computerized Histologic Risk Predictor (CHiRP) for early stage Lung Cancers Objectives: To develop and validate a computerized histologic risk predictor (CHiRP) to identify which early stage NSCLC patients, following surgery, will receive additional benefit from adjuvant chemotherapyNational institute of health2018–2023
Novel pharmacologic approach to enhance the epigenetic and immune priming effect of decitabine in patients with advanced non-small cell lung cancerAmerican Society of Clinical Oncology2015–2018
Young Investigtator AwardAmerican Society of Clinical Oncology2012–2013

Committees

Member, Cancer Education Committee, American Society of Clinical Oncology 2015 - Present
Education Committee, American Society of Clinical Oncology 2015 - Present
Member, Protocol Review and Monitoring Committee, Case Comprehensive Cancer Center, Cleveland, Ohio 2014 - 2015
Member, Yale-New Haven Hospital-Graduate Medical Education Committee 2012 - 2013